Anti-viral and Anti-Inflammatory Response: GoldenBiotech’s Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA

Taipei, June 29,2020. Golden Biotechnology Corp. (GoldenBiotech, 4132.TWO), a leading Taiwanese biopharmaceutical company, announced that the FDA approved its investigational new drug (IND) application for a Phase II clinical trial of  Antroquinonol (Hocena®) on COVID-19 patients in USA. GoldenBiotech has also applied for the US BARDA (Biomedical Advanced Research and Development Administration) CoronaWatch meeting. Future developmental planning of Antroquinonol in COVID-19 include joining the COVID-19 Candidate and Technologies Portal of the National Institutes of Health (NIH) and applying for the US emergency authorization (EUA) once it exhibits significant clinical results, all to expedite the meeting of the urgent market demand.

The Phase II trial will be a randomized, double-blinded, placebo-controlled study of Antroquinonol as a potential treatment option for mild-to-moderate pneumonia in COVID-19 patients, as measured by the proportion of patients alive and free of respiratory failure (i.e., need for invasive mechanical ventilation, non-invasive ventilation, high-flow oxygen, or extracorporeal membrane oxygenation [ECMO]) on Day 14.

Golden Biotechnology Corp.,leading in pharma and supplement products.New drug Antroquinonol(HOCENA) update for Covid-19 coronavirus study and clinical trial in USA. AML,NSCLC, Pancreatic cancer clinical trial achievement. Received Orphan Drug Designations for Pancreatic Cancer, AML and  HCC . Released Phase II trial of NSCLC  in the annual ASCO meeting. Joined with QUT ,J&J in Alzheimer's Disease study. Successful unblinding on clinical trial of hyperlipid. Visit our booth 4F, R410 or the online exhibition virtual booth. Register to watch and listen to "Company Presentation " of Golden Biotechnology Corporation.